If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor Multiple Sclerosis advisory service, Decision Resources is offering an exclusive analyst call entitled Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market? Because this analyst call will feature major findings, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. On June 22, Merck Serono announced it would no longer pursue global approval of cladribine, the company's novel oral immunosuppressant for the treatment of relapsing-remitting multiple sclerosis (RR-MS). Simultaneously, Merck Serono announced that it will withdraw the drug from the Australian and Russian markets, where oral cladribine is marketed under the brand name Movectro. A new clinical trial program would have been necessary to address the concerns of regulators in the United States and Europe regarding oral cladribine's risk/benefit profile, which led to the drug's rejection by these agencies earlier this year. The discontinuation of oral cladribine, once forecast to be the first oral disease-modifying drug to launch for the treatment of MS in the world's major markets, creates more opportunity for new MS therapies. In light of oral cladribine's demise, Decision Resources has updated its Pharmacor Multiple Sclerosis advisory service and market forecast. This 15-minute analyst call, presented by Decision Resources Senior Analyst Jonathan W. Searles, will answer the following questions:
Mr. Searles will conduct a live Q & A session after the presentation. Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market? July 6, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.
In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Jonathan W. Searles is a senior analyst on the central nervous system disorders team at Decision Resources. Prior to joining the company, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University. While earning his bachelor of arts degree, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.